Eiger BioPharmaceuticals, Inc. Stock News

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) during the fourth quarter, according to its most recent disclosure with the

Equities analysts expect that Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will announce earnings per share (EPS) of ($0.85) for the current quarter, Zacks Investment Research reports. Zero analysts hav

Eiger Biopharmaceuticals (NASDAQ:EIGR) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength

Wedbush analyst Liana Moussatos maintained a Buy rating on Eiger Biopharmaceuticals ( EIGR – Research Report ) today and set a price target of $33.00 . The company’s shares closed last Thursday at

Here's a roundup of top developments in the biotech space over the last 24 hours.On a day when the three major averages shed over 4% in reaction to bleak forecasts concerning the COVID-19 pandemic's

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today provided an update on the impact o

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report),

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed su

Potential Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shareholders may wish to note that the Founder, Jeffrey Glenn...

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report),

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...